Key facts
- This page summarizes Arvind Kush's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Jun 2026, 16:05.
Arvind Kush - 26 Jun 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)
- Reporting relationship
- Director
- Issuer ticker
- IKT
- Reported as of
- 26 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jun 2026, 16:05:07 UTC
- Prior SEC filing
- 02 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Iwicki, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arvind Kush filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 30 Jun 2026.
Change
- Previous filing in this sequence was filed on 02 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001986806
Primary reporting owner
Kush Arvind
- Relationship
- Director
- Address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON
- Signature
- /s/ Mark Iwicki, attorney-in-fact
- Signature date
- 30 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +155,000
- Change %
- Price
- $0.000000*
- Shares after
- 155,000
- Date
- 26 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 155,000
- Exercise price
- $1.91
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.